Competition is on the horizon for costly narcolepsy treatments
pharmaphorum
DECEMBER 14, 2022
But increased competition is on the horizon. Avadel Pharmaceuticals developed Lumryz, a sodium oxybate that is a once-daily, extended-release oral suspension that gained tentative FDA approval in July 2022. Competition starts to heat up. Classic treatment options. Xyrem is one of three that has a patent. About the author.
Let's personalize your content